BioNTech SE (NASDAQ:BNTX – Get Free Report) saw a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 2,110,000 shares, an increase of 18.5% from the July 31st total of 1,780,000 shares. Based on an average trading volume of 731,900 shares, the days-to-cover ratio is currently 2.9 days.
BioNTech Price Performance
Shares of BNTX stock opened at $125.08 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.56 and a quick ratio of 10.32. The company has a market capitalization of $30.14 billion, a P/E ratio of 7.01 and a beta of 0.18. The company’s 50-day simple moving average is $109.37 and its two-hundred day simple moving average is $116.43. BioNTech has a one year low of $95.50 and a one year high of $188.99.
BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.04. BioNTech had a return on equity of 21.46% and a net margin of 47.37%. The firm had revenue of $167.70 million during the quarter, compared to the consensus estimate of $628.13 million. During the same period in the previous year, the company posted $7.31 earnings per share. The firm’s quarterly revenue was down 94.8% on a year-over-year basis. As a group, equities analysts anticipate that BioNTech will post 6.12 EPS for the current year.
Analyst Ratings Changes
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. State of Wyoming purchased a new stake in shares of BioNTech during the second quarter valued at about $26,000. Global Retirement Partners LLC increased its position in shares of BioNTech by 7,125.0% during the second quarter. Global Retirement Partners LLC now owns 289 shares of the company’s stock worth $31,000 after purchasing an additional 285 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of BioNTech by 61.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 299 shares of the company’s stock valued at $32,000 after purchasing an additional 114 shares during the last quarter. Eagle Bay Advisors LLC purchased a new position in BioNTech during the 2nd quarter worth $33,000. Finally, Signaturefd LLC increased its position in BioNTech by 18,750.0% during the 1st quarter. Signaturefd LLC now owns 377 shares of the company’s stock valued at $47,000 after buying an additional 375 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
- Five stocks we like better than BioNTech
- How to Invest in Biotech Stocks
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- What is the price-to-earnings growth (PEG) ratio?
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- Stock Average Calculator
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.